Plasma Aβ₄₂/Aβ₄₀ is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum.

ABSTRACT:

Introduction

The availability of amyloid beta (Aβ) targeting therapies for Alzheimer's disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation.

Methods

We evaluated fully-automated Lumipulse plasma Aβ₄₂/Aβ₄₀ immunoassays for detecting cerebral Aβ in 457 clinically unimpaired (CU) and clinically impaired (CI) Stanford Alzheimer's Disease Research Center (Stanford ADRC) participants and 186 CU in the Stanford Aging and Memory Study (SAMS). Longitudinal change in ADRC plasma Aβ₄₂/Aβ₄₀ and cognition and cross-sectional associations with SAMS memory and tau positron emission tomography (PET) were examined.

Results

Plasma Aβ₄₂/Aβ₄₀ exhibited high perf

SUBMITTER: Trelle AN 

PROVIDER: S-EPMC11848181 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature